ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Gene fusion is another important type of mutation in tumors that may provide many neoantigens, which can be generated by mesenchymal deletion, chromosomal translocation or chromosomal inversion.28,75–77 Studies have shown that polypeptides derived from the different fusion regions of the proteins can be recognized by the patient’s own T cells, such as the BCR-ABL fusion protein produced by the translocation between chromosomes 9 and 22 in chronic myeloid leukemia (CML) patients and SYT-SSX1 fusion proteins produced by X and 18 chromosomal translocations in synovial sarcoma patients.